Ventyx Biosciences reported Phase 2 data showing its oral NLRP3 inhibitor VTX‑3232 produced rapid, large reductions in inflammatory biomarkers linked to cardiovascular risk. In a randomized, placebo‑controlled mid‑stage study in patients with obesity and CV risk factors the drug reduced high‑sensitivity C‑reactive protein (hsCRP) by roughly 78% compared with placebo and achieved statistically significant falls in IL‑6, Lp(a), fibrinogen and markers of liver inflammation. The program met its primary safety and tolerability endpoint and is being discussed with potential pharma partners to advance cardiovascular and neuroinflammatory indications.